COVID-19 infection and glucocorticoids: update from the Italian Society of Endocrinology Expert Opinion on steroid replacement in adrenal insufficiency

A M Isidori, G Arnaldi, M Boscaro, A Falorni, C Giordano, R Giordano, R Pivonello, R Pofi, V Hasenmajer, M A Venneri, E Sbardella, C Simeoli, C Scaroni, A Lenzi, A M Isidori, G Arnaldi, M Boscaro, A Falorni, C Giordano, R Giordano, R Pivonello, R Pofi, V Hasenmajer, M A Venneri, E Sbardella, C Simeoli, C Scaroni, A Lenzi

No abstract available

Keywords: Adrenal insufficiency; COVID-19; Glucocorticoids; SARS-CoV2.

Conflict of interest statement

AM.I. has received grants and advisory fees from Takeda and Novartis. G.A. has been Principal Investigator of Research Studies for Novartis; has received research grants from Novartis and Takeda; has received speaker fees from Novartis; and has received consulting fees from Novartis and Pfizer, Inc. as board member. M.B. has been Principal Investigator of Research Studies for Novartis; has been Investigator of Research Studies for Novartis, HRA Pharma and ViroPharma; and has received consulting fees from Novartis as board member. A.F. declares that he has received a speaker honorarium from Shire Italy S.p.A. C.G. has been Principal Investigator of Research Studies for Novo Nordisk and Lilly USA, LLC; has received research grants from Novo Nordisk and Lilly USA, LLC; has been an occasional consultant for Novartis, Pfizer, Inc., Ipsen and Shire; and has received speaker fees from Novo Nordisk, Lilly USA, LLC and Novartis. R.G. has been occasional consultant for Shire. R.P. has been Principal Investigator of Research Studies for Novartis, HRA Pharma, Ipsen, Shire, Corcept Therapeutics, Cortendo AB; Co-investigator of Research Studies for Pfizer; received research grants from Novartis, Pfizer, Ipsen, HRA Pharma, Shire, IBSA; has been an occasional consultant for Novartis, Ipsen, Pfizer, Shire, HRA Pharma, Cortendo AB, Ferring and Italfarmaco; and has received fees and honoraria for presentations from Novartis, Shire. C.S. has been occasional consultant for Shire and Ipsen. C.S. has been Principal Investigator of Research Studies for Novartis, Otsuka and Pfizer, Inc.; has been Co-investigator of Research Studies for Novartis and Lilly USA, LLC; has received research grants from Novartis, Lilly USA, LLC, Otsuka and Pfizer, Inc.; has been an occasional consultant for Novartis and Otsuka; and has received speaker fees for presentations from Otsuka and Lilly USA, LLC. A.L. has received grants and advisory fees from Takeda and Novartis. V.H., R.P., M.A.V and E.S. have no conflicts of interest.

Figures

Fig. 1
Fig. 1
Proposal for a stage-specific adjustment of glucocorticoid therapy in adrenal insufficient patients with COVID-19 infection

References

    1. Isidori AM, Arnaldi G, Boscaro M, Falorni A, Giordano C, Giordano R, Pivonello R, Pozza C, Sbardella E, Simeoli C, Scaroni C, Lenzi A, Italian Society of E Towards the tailoring of glucocorticoid replacement in adrenal insufficiency: the Italian Society of Endocrinology Expert Opinion. J Endocrinol Invest. 2019 doi: 10.1007/s40618-019-01146-y.
    1. Baud D, Qi X, Nielsen-Saines K, Musso D, Pomar L, Favre G. Real estimates of mortality following COVID-19 infection. Lancet Infect Dis. 2020 doi: 10.1016/S1473-3099(20)30195-X.
    1. Onder G, Rezza G, Brusaferro S. Case-fatality rate and characteristics of patients dying in relation to COVID-19 in Italy. JAMA. 2020 doi: 10.1001/jama.2020.4683.
    1. Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72314 cases from the Chinese center for disease control and prevention. JAMA. 2020 doi: 10.1001/jama.2020.2648.
    1. Newton AH, Cardani A, Braciale TJ. The host immune response in respiratory virus infection: balancing virus clearance and immunopathology. Semin Immunopathol. 2016;38(4):471–482. doi: 10.1007/s00281-016-0558-0.
    1. Shi Y, Wang Y, Shao C, Huang J, Gan J, Huang X, Bucci E, Piacentini M, Ippolito G, Melino G. COVID-19 infection: the perspectives on immune responses. Cell Death Differ. 2020 doi: 10.1038/s41418-020-0530-3.
    1. Sweeney RM, McAuley DF. Acute respiratory distress syndrome. Lancet. 2016;388(10058):2416–2430. doi: 10.1016/S0140-6736(16)00578-X.
    1. Wang F, Nie J, Wang H, Zhao Q, Xiong Y, Deng L, Song S, Ma Z, Mo P, Zhang Y. Characteristics of peripheral lymphocyte subset alteration in COVID-19 pneumonia. J Infect Dis. 2020 doi: 10.1093/infdis/jiaa150.
    1. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, Zhang L, Fan G, Xu J, Gu X, Cheng Z, Yu T, Xia J, Wei Y, Wu W, Xie X, Yin W, Li H, Liu M, Xiao Y, Gao H, Guo L, Xie J, Wang G, Jiang R, Gao Z, Jin Q, Wang J, Cao B. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497–506. doi: 10.1016/S0140-6736(20)30183-5.
    1. Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, Liu L, Shan H, Lei CL, Hui DSC, Du B, Li LJ, Zeng G, Yuen KY, Chen RC, Tang CL, Wang T, Chen PY, Xiang J, Li SY, Wang JL, Liang ZJ, Peng YX, Wei L, Liu Y, Hu YH, Peng P, Wang JM, Liu JY, Chen Z, Li G, Zheng ZJ, Qiu SQ, Luo J, Ye CJ, Zhu SY, Zhong NS, China Medical Treatment Expert Group for C Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020 doi: 10.1056/NEJMoa2002032.
    1. Figueroa-Parra G, Aguirre-Garcia GM, Gamboa-Alonso CM, Camacho-Ortiz A, Galarza-Delgado DA. Are my patients with rheumatic diseases at higher risk of COVID-19? Ann Rheum Dis. 2020 doi: 10.1136/annrheumdis-2020-217322.
    1. Halpin DMG, Faner R, Sibila O, Badia JR, Agusti A. Do chronic respiratory diseases or their treatment affect the risk of SARS-CoV-2 infection? Lancet Respir Med. 2020 doi: 10.1016/S2213-2600(20)30167-3.
    1. Wu C, Chen X, Cai Y, Xia J, Zhou X, Xu S, Huang H, Zhang L, Zhou X, Du C, Zhang Y, Song J, Wang S, Chao Y, Yang Z, Xu J, Zhou X, Chen D, Xiong W, Xu L, Zhou F, Jiang J, Bai C, Zheng J, Song Y. Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China. JAMA Intern Med. 2020 doi: 10.1001/jamainternmed.2020.0994.
    1. Chrousos GP. The hypothalamic-pituitary-adrenal axis and immune-mediated inflammation. N Engl J Med. 1995;332(20):1351–1362. doi: 10.1056/NEJM199505183322008.
    1. Ruan SY, Lin HH, Huang CT, Kuo PH, Wu HD, Yu CJ. Exploring the heterogeneity of effects of corticosteroids on acute respiratory distress syndrome: a systematic review and meta-analysis. Crit Care. 2014;18(2):R63. doi: 10.1186/cc13819.
    1. Chaudhary NS, Donnelly JP, Moore JX, Baddley JW, Safford MM, Wang HE. Association of baseline steroid use with long-term rates of infection and sepsis in the REGARDS cohort. Crit Care. 2017;21(1):185. doi: 10.1186/s13054-017-1767-1.
    1. Venkatesh B, Finfer S, Myburgh J, Cohen J, Billot L. Long-term outcomes of the ADRENAL trial. N Engl J Med. 2018;378(18):1744–1745. doi: 10.1056/NEJMc1803563.
    1. Annane D, Renault A, Brun-Buisson C, Megarbane B, Quenot JP, Siami S, Cariou A, Forceville X, Schwebel C, Martin C, Timsit JF, Misset B, Ali Benali M, Colin G, Souweine B, Asehnoune K, Mercier E, Chimot L, Charpentier C, Francois B, Boulain T, Petitpas F, Constantin JM, Dhonneur G, Baudin F, Combes A, Bohe J, Loriferne JF, Amathieu R, Cook F, Slama M, Leroy O, Capellier G, Dargent A, Hissem T, Maxime V, Bellissant E. Hydrocortisone plus fludrocortisone for adults with septic shock. N Engl J Med. 2018;378(9):809–818. doi: 10.1056/NEJMoa1705716.
    1. Zhou YH, Qin YY, Lu YQ, Sun F, Yang S, Harypursat V, Tang SQ, Huang YQ, He XQ, Zeng YM, Li Y, Xu XL, Zhao T, Chen YK. Effectiveness of glucocorticoid therapy in patients with severe novel coronavirus pneumonia: protocol of a randomized controlled trial. Chin Med J (Engl) 2020 doi: 10.1097/CM9.0000000000000791.
    1. Teblick A, Peeters B, Langouche L, Van den Berghe G. Adrenal function and dysfunction in critically ill patients. Nat Rev Endocrinol. 2019;15(7):417–427. doi: 10.1038/s41574-019-0185-7.
    1. Russell CD, Millar JE, Baillie JK. Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury. Lancet. 2020;395(10223):473–475. doi: 10.1016/S0140-6736(20)30317-2.
    1. Kaiser UB, Mirmira RG, Stewart PM. Our response to COVID-19 as endocrinologists and diabetologists. J Clin Endocrinol Metab. 2020 doi: 10.1210/clinem/dgaa148.
    1. Isidori AM, Venneri MA, Graziadio C, Simeoli C, Fiore D, Hasenmajer V, Sbardella E, Gianfrilli D, Pozza C, Pasqualetti P, Morrone S, Santoni A, Naro F, Colao A, Pivonello R, Lenzi A. Effect of once-daily, modified-release hydrocortisone versus standard glucocorticoid therapy on metabolism and innate immunity in patients with adrenal insufficiency (DREAM): a single-blind, randomised controlled trial. Lancet Diabetes Endocrinol. 2018;6(3):173–185. doi: 10.1016/S2213-8587(17)30398-4.
    1. Arafah BM. Perioperative glucocorticoid therapy for patients with adrenal insufficiency: dosing based on pharmacokinetic data. J Clin Endocrinol Metab. 2020 doi: 10.1210/clinem/dgaa042.
    1. Castanon-Cervantes O, Wu M, Ehlen JC, Paul K, Gamble KL, Johnson RL, Besing RC, Menaker M, Gewirtz AT, Davidson AJ. Dysregulation of inflammatory responses by chronic circadian disruption. J Immunol. 2010;185(10):5796–5805. doi: 10.4049/jimmunol.1001026.
    1. Polidarova L, Houdek P, Sladek M, Novosadova Z, Pacha J, Sumova A. Mechanisms of hormonal regulation of the peripheral circadian clock in the colon. Chronobiol Int. 2017;34(1):1–16. doi: 10.1080/07420528.2016.1231198.
    1. Coiffard B, Diallo AB, Culver A, Mezouar S, Hammad E, Vigne C, Nicolino-Brunet C, Dignat-George F, Baumstarck K, Boucekine M, Leone M, Mege JL. Circadian rhythm disruption and sepsis in severe trauma patients. Shock. 2019;52(1):29–36. doi: 10.1097/SHK.0000000000001241.
    1. Gibbison B, Keenan DM, Roelfsema F, Evans J, Phillips K, Rogers CA, Angelini GD, Lightman SL. Dynamic pituitary–adrenal interactions in the critically ill after cardiac surgery. J Clin Endocrinol Metab. 2020 doi: 10.1210/clinem/dgz206.
    1. Pivonello R, Simeoli C, De Martino MC, Cozzolino A, De Leo M, Iacuaniello D, Pivonello C, Negri M, Pellecchia MT, Iasevoli F, Colao A. Neuropsychiatric disorders in Cushing's syndrome. Front Neurosci. 2015;9:129. doi: 10.3389/fnins.2015.00129.
    1. Prete A, Taylor AE, Bancos I, Smith DJ, Foster MA, Kohler S, Fazal-Sanderson V, Komninos J, O'Neil DM, Vassiliadi DA, Mowatt CJ, Mihai R, Fallowfield JL, Annane D, Lord JM, Keevil BG, Wass JAH, Karavitaki N, Arlt W. Prevention of adrenal crisis: cortisol responses to major stress compared to stress dose hydrocortisone delivery. J Clin Endocrinol Metab. 2020 doi: 10.1210/clinem/dgaa133.
    1. Alhazzani W, Moller MH, Arabi YM, Loeb M, Gong MN, Fan E, Oczkowski S, Levy MM, Derde L, Dzierba A, Du B, Aboodi M, Wunsch H, Cecconi M, Koh Y, Chertow DS, Maitland K, Alshamsi F, Belley-Cote E, Greco M, Laundy M, Morgan JS, Kesecioglu J, McGeer A, Mermel L, Mammen MJ, Alexander PE, Arrington A, Centofanti JE, Citerio G, Baw B, Memish ZA, Hammond N, Hayden FG, Evans L, Rhodes A. Surviving sepsis campaign: guidelines on the management of critically ill adults with coronavirus disease 2019 (COVID-19) Intensive Care Med. 2020 doi: 10.1007/s00134-020-06022-5.
    1. Arlt W, Society for Endocrinology Clinical C SOCIETY FOR ENDOCRINOLOGY ENDOCRINE EMERGENCY GUIDANCE: Emergency management of acute adrenal insufficiency (adrenal crisis) in adult patients. Endocr Connect. 2016;5(5):G1–G3. doi: 10.1530/EC-16-0054.
    1. Pivonello R, Isidori AM, De Martino MC, Newell-Price J, Biller BM, Colao A. Complications of Cushing's syndrome: state of the art. Lancet Diabetes Endocrinol. 2016;4(7):611–629. doi: 10.1016/S2213-8587(16)00086-3.
    1. Isidori AM, Minnetti M, Sbardella E, Graziadio C, Grossman AB. Mechanisms in endocrinology: the spectrum of haemostatic abnormalities in glucocorticoid excess and defect. Eur J Endocrinol. 2015;173(3):R101–113. doi: 10.1530/EJE-15-0308.

Source: PubMed

Sponzoři a spolupracovníci

Zdravotní podmínky

Drogové intervence

3
Předplatit